HCPCS Level II code C1767 designates an implantable, non-rechargeable neurostimulator generator— the implanted power source for neurostimulation systems. This code is relevant nationally for hospitals, ambulatory surgical centers, neurosurgeons, pain specialists, and device manufacturers because it identifies a high-cost durable implantable device used in chronic pain and neurological disorder management. Coverage and reimbursement for C1767 affect access to neuromodulation therapies and facility billing for device implantation.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of payer coverage patterns, common site-of-service designations, and typical clinical use cases. The publication summarizes available benchmarks for device reimbursement, highlights policy and coverage considerations that influence utilization, and provides clinical context about when implantable, non-rechargeable generators are used versus alternative devices.

The report is intended for revenue cycle managers, hospital billing teams, clinicians involved in device selection, and policy analysts seeking a national perspective on coding, billing, and coverage issues surrounding implantable neurostimulator generators.